Business
Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update
Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all
About this update from Vivos Therapeutics, Inc.
[{"type":"image","alt":"Vivos Therapeutics, Inc","displaySize":"","headline":null,"caption":"Vivos Therapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":148,"height":46,"url":"https://media.zenfs.com/en/globenewswire.com/452f3e3cd3796a0ed8557400112a2519"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o.bVqaj5F3NG9.btjYGvyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTY1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/452f3e3cd3796a0ed8557400112a2519","width":148,"height":46}},"lazy":false},{"type":"text","content":"Year over year product revenue increased 26%","length":44,"tagName":"p"},{"type":"text","content":"Operating expenses declined 21% and year over year operating loss decreased 35%","length":79,"tagName":"p"},{"type":"text","content":"Management to Host Conference Call today at 5:00 pm ET","length":54,"tagName":"p"},{"type":"text","content":"LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults) and moderate to severe OSA in children ages 6 - 17), today reported financial results and operating highlights for the full year ended December 31, 2024.","length":527,"tagName":"p"},{"type":"text","content":"Full Year 2024 Financial and Operating Summary","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue increased approximately $1.2 million, or 9%, to $15.0 million for the full year ended December 31, 2024, compared to $13.8 million for the year ended December 31, 2023. The increase in revenue was mainly due to higher product revenue offset by decreased revenue from fewer Vivos Integrated Practice (VIP) enrollments, which decrease occurred as part of Vivos’ change in marketing and sales strategy during the year to focus on provider-based alliances;","length":460,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross profit was $9.0 million for the full year ended December 31, 2024 compared with $8.3 million for the full year ended December 31, 2023, attributable to the increase in revenue;","length":182,"tagName":"p"}]},{"val":[{"type":"text","content":"Gr...